CePasR: Antistaphylococcal Betalactam and Emergence of Resistance

Sponsor

Central Hospital, Nancy, France (Other)

Overall Status

Completed

CT.gov ID

NCT05939479

Collaborator

(none)

644

Enrollment

Location

Actual Duration (Months)

9.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Antistaphylococcal penicillins are recommanded as first-line agent in methicillin-suceptible Staphylococcus aureus bacteraemia. Several studies in progress are investigating the efficacy and safety of cefazolin compared with antistaphylococcal penicillins. Cefazolin has broader spectrum than antistaphylococcal penicillins. The hypothesis of this project is that cefazoline could be responsible for a higher rate of bacterial resistance. The aim is to study the association between the emergence of bacterial resistance and the consumption of cefazolin and antistaphylococcal penicillins.

Condition or Disease	Intervention/Treatment	Phase
Bacterial Resistance Methicillin-Sensitive Staphylococcus Aureus Infection

Study Design

Study Type:

Observational

Actual Enrollment :

644 participants

Observational Model:

Ecologic or Community

Time Perspective:

Retrospective

Official Title:

Impact of Antistaphylococcal Penicillins and Cefazolin on the Emergence of Resistance in French Hospitals

Actual Study Start Date :

Jan 1, 2018

Actual Primary Completion Date :

May 1, 2023

Actual Study Completion Date :

Jun 1, 2023

Outcome Measures

Primary Outcome Measures

Association between the cefazolin/antistaphylococcal penicillins consumptions and the resistant bacteria emergence [Between the first january 2018 and the 31st december 2022]
The total consumption of antibiotics (expressed as number of Defined Daily Doses (DDD) per 1000 inhabitants per day) will be correlate with the resistant bacteria emergence (only incidence for each bacterial strain)

Secondary Outcome Measures

Factors associated with the emergence of resistant bacteria [Between the first january 2018 and the 31st december 2022]
Factors associated with the emergence of resistant bacteria will be described by a Cox model: hospital size (number of beds), location in France, activities (intensive care, surgery, etc.), type of antibiotics and intensity of consumption expressed in number of defined daily doses (DDD).
Factors associated with the consumption of antibiotics [Between the first january 2018 and the 31st december 2022]
Factors associated with the emergence of resistant bacteria will be described by a Cox model: hospital size (number of beds), location in France, activities (intensive care, surgery, etc.) and type of bacterial strain indentified (resistant or not).
Evolution of resistance in French hospitals [Between the first january 2018 and the 31st december 2022]
For each year, bacterial resistance will be described, in France and in each hospital, in the form of a quantitative variable: number of resistant bacterial strains isolated for each year (number of resistant strains / total number of strains).
Evolution of antibiotics consumption in French hospitals [Between the first january 2018 and the 31st december 2022]
For each year, antibiotic consumption will be described, in France and in each hospital, in the form of a quantitative variable (expressed as number of Defined Daily Doses (DDD) per 1000 inhabitants per day)

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria: French hospitals which have collected their consumption and resistance data on the French national database named CONSORES (From 2019 to 2022)